Increased rRNA levels in cancer cells can contribute to cancer progression. By blocking the binding of hnRNP k to rRNA and reducing its levels in non-SG foci cells, eIF3f lowers its protection.In chemotherapy, eIF3f knockdown cells are more susceptible to gemcitabine. The gene discussed is HNRNPK; the disease is cancer.